Published in Clin Cancer Res on May 01, 2007
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer (2009) 2.01
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res (2009) 2.00
MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst (2010) 1.29
Recent advances in the molecular understanding of glioblastoma. J Neurooncol (2012) 1.29
Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One (2011) 1.27
Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev (2014) 1.22
Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol (2014) 1.17
The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia (2008) 1.13
Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology (2011) 1.09
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med (2012) 1.03
Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiol (2012) 1.01
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol (2014) 0.99
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol (2014) 0.93
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ (2012) 0.90
Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett (2014) 0.90
Temozolomide in malignant glioma. Onco Targets Ther (2010) 0.89
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. Childs Nerv Syst (2011) 0.88
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol (2015) 0.87
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. World J Surg Oncol (2015) 0.84
Applications of emerging molecular technologies in glioblastoma multiforme. Expert Rev Neurother (2008) 0.83
Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. Biomed Res Int (2015) 0.83
Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited. Neuroradiology (2011) 0.82
Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. Cancer Manag Res (2017) 0.75
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2004) 2.70
Spontaneous intracranial hypotension syndrome: a novel speculative physiopathological hypothesis and a novel patch method in a series of 28 consecutive patients. J Neurosurg (2010) 2.38
Conversion of the BASE prion strain into the BSE strain: the origin of BSE? PLoS Pathog (2007) 1.97
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol (2006) 1.92
Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res (2006) 1.89
Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia (2006) 1.82
Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurg Focus (2014) 1.74
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol (2007) 1.73
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev (2015) 1.70
Surgical site infections after elective neurosurgery: a survey of 1747 patients. Neurosurgery (2008) 1.66
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2007) 1.59
Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. Radiology (2009) 1.56
Image-guided endoscopic transnasal removal of recurrent pituitary adenomas. Neurosurgery (2002) 1.55
Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther (2006) 1.54
Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry (2012) 1.54
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
A novel impermeable adhesive membrane to reinforce dural closure: a preliminary retrospective study on 119 consecutive high-risk patients. World Neurosurg (2011) 1.53
Household water source and the risk of childhood brain tumours: results of the SEARCH International Brain Tumor Study. Int J Epidemiol (2004) 1.49
Acute late-onset encephalopathy after radiotherapy: an unusual life-threatening complication. Neurology (2013) 1.42
Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery (2003) 1.41
Decrease in circulating endothelial progenitor cells in treated glioma patients. J Neurooncol (2012) 1.38
The role of indocyanine green videoangiography (ICGV) in surgery of parasagittal meningiomas. Acta Neurochir (Wien) (2013) 1.38
Spontaneous intracranial hypotension with deep brain swelling. Brain (2007) 1.36
Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. Acta Neurochir (Wien) (2013) 1.34
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol (2003) 1.30
Presurgical functional MR imaging of language and motor functions: validation with intraoperative electrocortical mapping. Radiology (2008) 1.23
CD133 is essential for glioblastoma stem cell maintenance. Stem Cells (2013) 1.21
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Hypothalamic stimulation for intractable cluster headache: long-term experience. Neurology (2006) 1.19
Meningiomas invading the superior sagittal sinus: surgical experience in 108 cases. Neurosurgery (2004) 1.19
New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke (2002) 1.18
A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med (2008) 1.16
NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget (2012) 1.15
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol (2010) 1.13
Stimulation of the globus pallidus internus for childhood-onset dystonia. Mov Disord (2005) 1.13
Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen (2009) 1.12
Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: clinical results and FMRI correlations. Headache (2010) 1.12
Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 1.11
Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev (2012) 1.10
Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol (2007) 1.10
Dural sinus thrombosis in spontaneous intracranial hypotension: Hypotheses on possible mechanisms. J Neurol (2006) 1.09
Large-scale functional organization of long-range chromatin interaction networks. Cell Rep (2012) 1.08
The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation. Neurobiol Dis (2005) 1.08
Periventricular nodular heterotopia: classification, epileptic history, and genesis of epileptic discharges. Epilepsia (2006) 1.08
CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther (2009) 1.08
Neuroradiological diagnosis of Chiari malformations. Neurol Sci (2011) 1.07
Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer (2004) 1.06
Endoscopic third ventriculostomy in idiopathic normal pressure hydrocephalus: an Italian multicenter study. Neurosurgery (2008) 1.06
Neuritis ossificans. J Neurosurg (2014) 1.06
Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neurosci Lett (2004) 1.05
Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol (2008) 1.02
Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol (2009) 1.02
Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med (2009) 1.01
Deep brain stimulation to relieve drug-resistant SUNCT. Ann Neurol (2005) 1.01
Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res (2014) 1.00
Functional MRI/event-related potential study of sensory consonance and dissonance in musicians and nonmusicians. Neuroreport (2009) 1.00
Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer (2002) 1.00
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. Neuro Oncol (2014) 0.99
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol (2012) 0.99
Quantitation of normal metabolite concentrations in six brain regions by in-vivoH-MR spectroscopy. J Med Phys (2010) 0.97
Microvascular decompression for glossopharyngeal neuralgia: a long-term retrospectic review of the Milan-Bologna experience in 31 consecutive cases. Acta Neurochir (Wien) (2009) 0.97
Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci (2013) 0.97
Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther (2007) 0.97
CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. J Neurooncol (2004) 0.97